Want to see IN:ASTRAZEN full AI Analyst Report?
ASTRAZEN Stock Chart & Stats
₹8431.70
₹585.60(8.51%)
At close: 4:00 PM EST
₹8431.70
₹585.60(8.51%)
Day’s Range― - ―
52-Week Range₹7,490.00 - ₹9,850.00
Previous CloseN/A
Volume65.42K
Average Volume (3M)602.00
Market Cap
₹190.72B
Enterprise Value₹190.61K
Total Cash (Recent Filing)₹4.48B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)112.6
Beta0.64
Next Earnings
Nov 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.47%
Share Statistics
EPS (TTM)67.85
Shares Outstanding25,000,000
10 Day Avg. Volume682
30 Day Avg. Volume602
Financial Highlights & Ratios
PEG Ratio1.67
Price to Book (P/B)22.24
Price to Sales (P/S)8.53
P/FCF Ratio6.05K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Revenue ScalingMeaningful multi-year revenue expansion indicates continued demand for the company’s branded prescription portfolio. Sustained top-line growth can support operating scale and reinforce market reach across hospitals, pharmacies, and institutional channels.
Conservative Balance SheetLow leverage provides financial resilience and limits interest-related pressure on earnings. The company retains flexibility to fund commercial activity, inventory, and portfolio expansion while remaining better positioned to absorb volatility than highly indebted peers.
Broad Specialty PortfolioExposure across several specialty therapeutic areas reduces dependence on a single disease segment and supports multiple long-term demand drivers. The branded prescription model and healthcare-provider relationships can also strengthen recurring physician-led product adoption.
Bears Say
Margin CompressionThe sharp decline in gross and operating margins indicates weaker profitability quality despite revenue growth. If caused by product mix, costs, or commercial pressure, sustained compression could limit operating leverage and reduce the earnings benefit of future sales expansion.
Weak Cash ConversionThe steep deterioration in operating and free cash flow raises concern about working-capital requirements or higher cash usage. Persistently weak conversion would reduce internally generated funding for growth, dividends, and portfolio investment despite reported earnings.
Competitive And Regulatory ExposureThe business operates in an environment where generic competition and price regulation can constrain revenue realization and margins. These pressures are structural to Indian pharmaceuticals and may limit the company’s ability to fully monetize branded specialty medicines over time.
AstraZeneca Pharma India Limited News
ASTRAZEN FAQ
What was AstraZeneca Pharma India Limited’s price range in the past 12 months?
AstraZeneca Pharma India Limited lowest stock price was ₹7490.00 and its highest was ₹9850.00 in the past 12 months.
What is AstraZeneca Pharma India Limited’s market cap?
AstraZeneca Pharma India Limited’s market cap is ₹190.72B.
When is AstraZeneca Pharma India Limited’s upcoming earnings report date?
AstraZeneca Pharma India Limited’s upcoming earnings report date is Nov 14, 2026 which is in 86 days.
How were AstraZeneca Pharma India Limited’s earnings last quarter?
AstraZeneca Pharma India Limited released its earnings results on Aug 10, 2026. The company reported ₹15.172 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is AstraZeneca Pharma India Limited overvalued?
According to Wall Street analysts AstraZeneca Pharma India Limited’s price is currently Overvalued.
Does AstraZeneca Pharma India Limited pay dividends?
AstraZeneca Pharma India Limited pays a Annually dividend of ₹36 which represents an annual dividend yield of 0.47%. See more information on AstraZeneca Pharma India Limited dividends here
What is AstraZeneca Pharma India Limited’s EPS estimate?
AstraZeneca Pharma India Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AstraZeneca Pharma India Limited have?
AstraZeneca Pharma India Limited has 25,000,000 shares outstanding.
What happened to AstraZeneca Pharma India Limited’s price movement after its last earnings report?
AstraZeneca Pharma India Limited reported an EPS of ₹15.172 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.354%.
Which hedge fund is a major shareholder of AstraZeneca Pharma India Limited?
Currently, no hedge funds are holding shares in IN:ASTRAZEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited operates as a biopharmaceutical entity, engaged in the development, production, and global commercialization of pharmaceutical products, serving both the Indian domestic market and international clientele. The company offers an extensive range of medications, including treatments for cardiovascular conditions and diabetes, marketed under brands such as Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN. Its respiratory portfolio features products like Symbicort and FASENRA, while its oncology division provides various cancer therapies, including LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex. Furthermore, the firm extends its product line to encompass therapeutic solutions for renal, metabolic, and immunological disorders. Beyond its pharmaceutical offerings, AstraZeneca Pharma India Limited also provides clinical trial services. Established in 1979, the company is based in Bengaluru, India, and functions as a subsidiary of AstraZeneca Pharmaceuticals AB.
Technical Analysis
Dr. Reddy's Laboratories Ltd.
―
Glenmark Pharmaceuticals Limited
―
Lupin Limited
―
Sun Pharmaceutical Industries Limited
―
Torrent Pharmaceuticals Ltd
―